Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07787273 is registered in ClinicalTrials.gov with Hefei Cancer Hospital of the Chinese Academy of Sciences as lead sponsor.

NCT NCT07787273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07787273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Efficacy and Safety of Interferon Gamma Combined With Camrelizumab for Neoadjuvant Therapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Lead sponsor
Hefei Cancer Hospital of the Chinese Academy of Sciences
Phase
Phase 2
Overall status
Recruiting
Start date
March 20, 2026
Completion date
December 31, 2028
Enrollment
84 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

camrelizumab, locally advanced esophageal squamous cell carcinoma, neoadjuvant therapy